Natco Pharma Limited Financial Ratios
NATCOPHARM · Healthcare · Current price ₹785.2
P/E ratio
9.9x
P/B ratio
1.6x
ROE
15.4%
ROCE
15.8%
Debt / Equity
0.08
Dividend yield
0.2%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 9.9x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 1.6x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 15.4% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 15.8% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.08 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Natco Pharma Limited's latest numbers.
Natco Pharma Limited profitability
Natco Pharma Limited generates a return on equity of 15.4% and a return on capital employed of 15.8%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.08 and a P/E of 9.9x, Natco Pharma Limited is conservatively financed. Our overall business-quality score for the company is 6.4 / 10.
Understand the ratios
More on Natco Pharma Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.